 Connection
Charles Dinarello to Placebos
This is a "connection" page, showing publications Charles Dinarello has written about Placebos.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.086 |
|
|
|
-
Kanni T, Argyropoulou M, Dinarello CA, Simard J, Giamarellos-Bourboulis EJ. MABp1 targeting interleukin-1a in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open-label extension period. Clin Exp Dermatol. 2021 Jan; 46(1):162-163.
Score: 0.039
-
Cavelti-Weder C, Babians-Brunner A, Keller C, Stahel MA, Kurz-Levin M, Zayed H, Solinger AM, Mandrup-Poulsen T, Dinarello CA, Donath MY. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care. 2012 Aug; 35(8):1654-62.
Score: 0.022
-
Pott GB, Sailer CA, Porat R, Peskind RL, Fuchs AC, Angel JB, Skolnik PR, Jacobson MA, Giordano MF, Lebeaut A, Grint PC, Dinarello CA, Shapiro L. Effect of a four-week course of interleukin-10 on cytokine production in a placebo-controlled study of HIV-1-infected subjects. Eur Cytokine Netw. 2007 Jun; 18(2):49-58.
Score: 0.016
-
Dinarello CA, Wolff SM, Goldfinger SE, Dale DC, Alling DW. Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med. 1974 Oct 31; 291(18):934-7.
Score: 0.007
-
Wolff SM, Dinarello CA, Dale DC, Goldfinger SE, Alling DW. Colchicine therapy of familial Mediterranean fever. Trans Assoc Am Physicians. 1974; 87:186-94.
Score: 0.002
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|